These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 17522559

  • 1. Intramuscular aripiprazole in the control of agitation.
    Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade R, Pikalov AA, Crandall DT.
    J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
    [Abstract] [Full Text] [Related]

  • 2. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.
    Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, Oren DA.
    J Clin Psychopharmacol; 2007 Apr; 27(2):171-6. PubMed ID: 17414241
    [Abstract] [Full Text] [Related]

  • 3. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
    Andrezina R, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, McQuade RD.
    Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
    Daniel DG, Currier GW, Zimbroff DL, Allen MH, Oren D, Manos G, McQuade R, Pikalov AA, Crandall DT.
    J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
    [Abstract] [Full Text] [Related]

  • 5. Intramuscular aripiprazole in the acute management of psychomotor agitation.
    De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, De Persis S, Piazzi G, Simonetti A, Telesforo CL, Sciarretta A, Caccia F, Gentile G, Kotzalidis GD, Girardi P.
    Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
    [Abstract] [Full Text] [Related]

  • 6. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, Iwamoto T.
    Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
    Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA.
    J Clin Psychiatry; 2007 Jan; 68(1):111-9. PubMed ID: 17284138
    [Abstract] [Full Text] [Related]

  • 8. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
    Huang CL, Hwang TJ, Chen YH, Huang GH, Hsieh MH, Chen HH, Hwu HG.
    J Formos Med Assoc; 2015 May; 114(5):438-45. PubMed ID: 25791540
    [Abstract] [Full Text] [Related]

  • 9. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L.
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [Abstract] [Full Text] [Related]

  • 10. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW.
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia.
    Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA.
    J Am Med Dir Assoc; 2009 Jan; 10(1):21-7. PubMed ID: 19111849
    [Abstract] [Full Text] [Related]

  • 12. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T, Samalin L, Llorca PM.
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
    Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, McQuade R, Tran QV, Pikalov A, Assunção-Talbott S.
    J Psychopharmacol; 2010 Jul; 24(7):1019-29. PubMed ID: 20008446
    [Abstract] [Full Text] [Related]

  • 14. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A.
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [Abstract] [Full Text] [Related]

  • 15. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [Abstract] [Full Text] [Related]

  • 16. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.
    Kittipeerachon M, Chaichan W.
    Schizophr Res; 2016 Oct; 176(2-3):231-238. PubMed ID: 27461399
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN.
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [Abstract] [Full Text] [Related]

  • 18. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J.
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [Abstract] [Full Text] [Related]

  • 19. Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
    Coley KC, Scipio TM, Ruby C, Lenze EJ, Fabian TJ.
    J Psychiatr Pract; 2009 Mar; 15(2):150-3. PubMed ID: 19339850
    [Abstract] [Full Text] [Related]

  • 20. Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms.
    Thase ME, Bowden CL, Nashat M, Eudicone JM, Marcus R, McQuade RD, Carlson BX.
    Int J Psychiatry Clin Pract; 2012 Jun; 16(2):121-31. PubMed ID: 22296512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.